<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article5</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/CURE" style="display:block; margin-bottom:10px;">CURE Original</a></li>
<h2><strong>CURE</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Clopidogrel in Patients with Acute Coronary Syndromes". The New England Journal of Medicine. 2001. 345(7):494-502. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcomes<br/>
8.2 Secondary Outcomes<br/>
9 Safety<br/>
10 Subgroup Analyses<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with acute coronary syndromes without ST-segment elevation, does the addition of clopidogrel to aspirin reduce the risk of cardiovascular events?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with acute coronary syndromes without ST-segment elevation, treatment with clopidogrel plus aspirin reduced the risk of cardiovascular death, myocardial infarction, or stroke compared with aspirin alone but increased the risk of major bleeding.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
<hr/><br/>
<h2><strong>Guidelines recommend dual antiplatelet therapy with clopidogrel and aspirin for patients with acute coronary syndrome without ST-segment elevation, particularly in those not undergoing revascularization procedures.</strong></h2><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, placebo-controlled trial<br/>
- N=12,562 <br/>
- Clopidogrel + aspirin (n=6259)<br/>
- Placebo + aspirin (n=6303)<br/>
- Setting: 482 centers in 28 countries<br/>
- Enrollment: 1998-2000<br/>
- Mean follow-up: 9 months<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcomes: Composite of death from cardiovascular causes, nonfatal MI, or stroke; and the composite of the first primary outcome or refractory ischemia<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Hospitalized within 24 hours after the onset of symptoms<br/>
- No ST-segment elevation<br/>
<br/>
Exclusion Criteria<br/>
- Contraindications to antiplatelet therapy<br/>
- High bleeding risk or severe heart failure<br/>
- Using oral anticoagulants<br/>
- Recent revascularization or glycoprotein IIb/IIIa receptor inhibitors<br/>
<br/>
Baseline Characteristics<br/>
- Similar across the groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Clopidogrel (300 mg loading dose, 75 mg daily) + aspirin (75 to 325 mg daily)<br/>
- Placebo + aspirin (75 to 325 mg daily)<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- First primary outcome: 9.3% in clopidogrel group vs. 11.4% in placebo group (RR 0.80; 95% CI, 0.72 to 0.90; P&lt;0.001)<br/>
- Second primary outcome: 16.5% in clopidogrel group vs. 18.8% in placebo group (RR 0.86, P&lt;0.001)<br/>
<br/>
Secondary Outcomes<br/>
- In-hospital severe ischemia, recurrent angina, heart failure, and revascularization were also significantly lower with clopidogrel.<br/>
<br/>
Safety<br/>
- Major bleeding: 3.7% in the clopidogrel group vs. 2.7% in the placebo group (RR 1.38; P=0.001)<br/>
- Life-threatening bleeding: no significant difference <br/>
<br/>
Subgroup Analyses<br/>
- Consistent benefits across various subgroups (e.g., different doses of aspirin, use of other medications, prior revascularization)<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- The original publication in NEJM
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
